Mark Munch Sells 2,000 Shares of Bruker (NASDAQ:BRKR) Stock

Bruker Corporation (NASDAQ:BRKR) VP Mark Munch sold 2,000 shares of the stock in a transaction that occurred on Friday, March 13th. The stock was sold at an average price of $35.44, for a total value of $70,880.00. Following the transaction, the vice president directly owned 128,443 shares in the company, valued at approximately $4,552,019.92. This represents a 1.53% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Mark Munch also recently made the following trade(s):

• On Thursday, January 15th, Mark Munch sold 2,000 shares of Bruker stock. The shares were sold at an average price of $49.20, for a total value of $98,400.00.
• On Monday, January 12th, Mark Munch sold 7,000 shares of Bruker stock. The stock was sold at an average price of $55.00, for a total value of $385,000.00.

Bruker Stock Performance

Bruker stock traded down $0.99 during mid-day trading on Monday, reaching $32.76. The company’s stock had a trading volume of 3,410,771 shares, compared to its average volume of 2,513,968. The company has a current ratio of 1.73, a quick ratio of 0.87 and a debt-to-equity ratio of 0.75. Bruker Corporation has a twelve month low of $28.53 and a twelve month high of $56.22. The business has a 50 day moving average price of $43.50 and a 200-day moving average price of $41.11. The firm has a market cap of $4.99 billion, a price-to-earnings ratio of -218.40, a PEG ratio of 2.02 and a beta of 1.19.

Bruker (NASDAQ:BRKR) last issued its earnings results on Thursday, February 12th. The medical research company reported $0.59 earnings per share for the quarter, missing analysts’ consensus estimates of $0.65 by ($0.06). Bruker had a positive return on equity of 13.56% and a negative net margin of 0.25%.The business had revenue of $977.20 million for the quarter, compared to analyst estimates of $964.61 million. During the same period last year, the company posted $0.76 earnings per share. The firm’s revenue for the quarter was down .2% on a year-over-year basis. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Sell-side analysts predict that Bruker Corporation will post 2.69 EPS for the current fiscal year.

Bruker Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, April 7th. Stockholders of record on Monday, March 23rd will be issued a dividend of $0.05 per share. The ex-dividend date of this dividend is Monday, March 23rd. This represents a $0.20 annualized dividend and a dividend yield of 0.6%. Bruker’s dividend payout ratio is -133.33%.

Analyst Ratings Changes

Several analysts recently issued reports on BRKR shares. Citigroup cut their price target on Bruker from $53.00 to $40.00 and set a “neutral” rating on the stock in a report on Friday, February 13th. Bank of America upped their price objective on Bruker from $43.00 to $60.00 and gave the stock a “buy” rating in a research note on Monday, December 15th. Zacks Research raised Bruker from a “strong sell” rating to a “hold” rating in a research report on Monday, December 8th. TD Cowen cut their target price on Bruker from $53.00 to $43.00 and set a “hold” rating on the stock in a research note on Friday, February 13th. Finally, UBS Group reissued a “neutral” rating and set a $49.00 price target on shares of Bruker in a report on Friday, February 13th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $50.38.

Hedge Funds Weigh In On Bruker

Several hedge funds and other institutional investors have recently made changes to their positions in BRKR. Los Angeles Capital Management LLC acquired a new stake in Bruker in the 4th quarter valued at approximately $26,000. Allworth Financial LP boosted its position in Bruker by 40.6% during the 3rd quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock worth $29,000 after acquiring an additional 257 shares during the period. Parallel Advisors LLC grew its stake in shares of Bruker by 121.0% in the fourth quarter. Parallel Advisors LLC now owns 875 shares of the medical research company’s stock worth $41,000 after purchasing an additional 479 shares in the last quarter. Spire Wealth Management grew its stake in shares of Bruker by 85.3% in the third quarter. Spire Wealth Management now owns 1,445 shares of the medical research company’s stock worth $47,000 after purchasing an additional 665 shares in the last quarter. Finally, Summit Securities Group LLC acquired a new position in shares of Bruker during the fourth quarter valued at $50,000. 79.52% of the stock is currently owned by institutional investors and hedge funds.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.